News and Trends 19 Dec 2022
Sanofi and Innate Pharma expand natural killer cell deal
Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi…